Logo
Homepage
Explore Our Models
Contact
Subscribe
Models
Genetically Engineered Animals
Knockout Mice
Knockout Rats
Knockin Mice
Knockin Rats
Transgenic Mice
Transgenic Rats
Model Generation Techniques
Turboknockout<sup>®</sup> Gene Targeting
ES Cell Gene Targeting
Targeted Gene Editing
Regular Transgenic
PiggyBac Transgenesis
BAC Transgenic
Research Models
HUGO-GT™ Humanized Mice
Cre Mouse Lines
Humanized Target Gene Models
Metabolic Disease Models
Ophthalmic Disease Models
Neurological Disease Models
Autoimmune Disease Models
Immunodeficient Mouse Models
Humanized Immune System Mouse Models
Oncology & Immuno-oncology Models
Covid-19 Mouse Models
MouseAtlas Model Library
Knockout Cell Line Product Catalog
Tumor Cell Line Product Catalog
AAV Standard Product Catalog
Animal Supporting Services
Breeding Services
Cryopreservation & Recovery
Phenotyping Services
BAC Modification
Custom Cell Line Models
Induced Pluripotent Stem Cells (iPSCs)
Knockout Cell Lines
Knockin Cell Lines
Point Mutation Cell Lines
Overexpression Cell Lines
Virus Packaging
Adeno-associated Virus (AAV) Packaging
Lentivirus Packaging
Adenovirus Packaging
CRO Services
By Therapeutic Area
Oncology
Ophthalmology
Neuroscience
Metabolic & Cardiovascular Diseases
Autoimmune & Inflammatory
By Drug Type
AI-Powered AAV Discovery
Gene Therapy
Oligonucleotide Therapy
Antibody Therapy
Cell Immunotherapy
Resources
Promotion
Events & Webinars
Newsroom
Blogs & Insights
Resource Vault
Reference Databases
Peer-Reviewed Citations
Rare Disease Data Center
AbSeek
Cell iGeneEditor™ System
OriCell
Quality
Facility Overview
Animal Health & Welfare
Health Reports
About Us
Corporate Overview
Our Partners
Careers
Contact Us
HUGO-GTTM: Revolutionizing Humanized Mouse Models
Accelerating Drug Discovery with Precise Genome-Wide Humanization Experience accuracy and reliability in preclinical studies with HUGO-GT™ models, powered by our proprietary TurboKnockout-Pro technology.
Accelerating Development
Ready-to-use models speed up translational research workflows
Natural Regulation
Human gene expression mimics endogenous spatial and temporal patterns
Accurate Gene Expression
Full-length hACE2 knock-in under native murine promoter
Overview
Product
FAQs
Overview
Elevate Your Gene Therapy Research with HUGO-GT™
HUGO-GT™ revolutionizes gene therapy research by seamlessly integrating complete human genes into mouse genomes. Our advanced humanized mouse models deliver precision in disease modeling and enhanced translational relevance. Powered by proprietary TurboKnockout-Pro technology, HUGO-GT™ accelerates model development while ensuring exceptional reproducibility. Partner with the platform trusted by leading research institutions and pharmaceutical companies to advance drug development, therapeutic efficacy studies, and translational research.Explore how HUGO-GT™ is reshaping gene therapy research and discover its transformative impact on ongoing studies.
Explore Ready-to-Use Mouse Models
Discover over 18,000 validated mouse strains—including knockout, conditional knockout, and humanized models—covering 20+ research areas such as oncology, neurology, and metabolism. All models are supported by detailed genotype data and guaranteed quality, helping you fast-track discovery with confidence.
You Might Also Be Interested In
MouseAtlas Model Library
Search and access curated genetically engineered mouse strains
Turboknockout® Gene Editing
Fast-track your research with our efficient gene targeting service.
Ophthalmic CRO Platform
Ocular disease models and IND-ready drug evaluation workflows
Gene Therapy CRO Platform
AI-guided AAV design and full-spectrum preclinical validation
Neuroscience CRO Platform
Validated CNS models with behavioral and molecular efficacy data
Antibody Discovery CRO Platform
Human antibody mice and AI tools for rapid therapeutic validation
Product
Request a Product Quote
Select products from our catalogs and submit your request. Our team will get back to you with detailed information.
Full Name
Email
Phone Number
Organization
Job Role
Country
Catalog Type
Product Name
Quantity
Additional Comments
Cyagen values your privacy. We’d like to keep you informed about our latest offerings and insights. Your preferences:
You may unsubscribe from these communications at any time. See our Privacy Policy for details on opting out and data protection.
By clicking the button below, you consent to allow Cyagen to store and process the personal information submitted in this form to provide you the content requested.
Model Selection Made Simple
Access Our Model Library >>
Base Strain
Catalog Number
Catalog NumberNameBase StrainResearch ApplicationAction
C001600B6-hINHBE/obC57BL/6NCya;C57BL/6JCyaResearch on the obesity and type II diabetes；Research on the metabolic diseases associated with improper fat distribution and storage；Development of human INHBE-targeted therapies
C001789B6-hANGPTL7C57BL/6JCyaANGPTL7-targeted drug screening, development, and evaluation；Research on the pathological mechanisms and therapeutic approaches of glaucoma；Research on the pathological mechanisms and therapeutic approaches of type 2 diabetes mellitus (T2DM) and obstructive sleep apnea (OSA)
C001791B6-hIL1BC57BL/6NCyaIL1B-targeted drug screening, development, and evaluation；Research on the pathological mechanisms and therapeutic approaches of gout, rheumatoid arthritis (RA), recurrent pericarditis, type 2 diabetes (T2D), and other inflammatory and autoimmune diseases；Research on the pathological mechanisms and therapeutic approaches of cancers；Research on the pathological mechanisms and therapeutic approaches of neurodegenerative diseases
C001790B6-hTREM1C57BL/6NCyaTREM1-targeted drug screening, development, and evaluation；Research on the pathological mechanisms and therapeutic approaches of inflammatory diseases such as inflammatory bowel disease (IBD) and rheumatoid arthritis (RA)；Research on the pathological mechanisms and therapeutic approaches of cancers such as glioma and hepatocellular carcinoma；Research on the pathological mechanisms and therapeutic approaches of neurodegenerative diseases such as Parkinson's disease (PD) and Alzheimer's disease (AD)
C001779B6-hFOLH1 (hPSMA) C57BL/6NCyaFOLH1-targeted drug screening, development, and evaluation；Research on the pathological mechanisms and therapeutic approaches of hyperhomocysteinemia；Research on the pathological mechanisms and therapeutic approaches of various solid tumors like prostate cancer
C001787B6-hLAG3C57BL/6JCyaLAG3-targeted drug screening, development, and evaluation；Research on the pathological mechanisms and therapeutic approaches of malignant tumors such as melanoma, colorectal cancer, and non-small cell lung carcinoma；Research on the pathological mechanisms and therapeutic approaches of chronic infections including HIV infection, hepatitis B, and tuberculosis；Research on the pathological mechanisms and therapeutic approaches of autoimmune diseases like rheumatoid arthritis and Hashimoto's thyroiditis
C001809B6-hTSLPC57BL/6NCyaTSLP-targeted drug screening, development, and evaluation；Research on the pathological mechanisms and therapeutic approaches of allergic and inflammatory diseases
C001772B6-hIL13/hIL23AC57BL/6NCyaScreening and development of IL13/IL23A-targeted therapeutics, and preclinical pharmacodynamic and safety evaluations；Research on the pathological mechanisms and therapeutic strategies for allergic and inflammatory diseases, immune-related disorders, and cancer
C001799B6-hNRLC57BL/6JCyaNRL-targeted drug screening, development, and evaluation；Research on the pathological mechanisms and therapeutic approaches of various inherited retinal degenerative diseases such as Retinitis Pigmentosa (RP)
C001819B6-hTTNC57BL/6NCyaTTN-targeted drug screening, development, and evaluation；Research on the pathological mechanisms and therapeutic approaches of genetic muscle diseases such as familial dilated cardiomyopathy (DCM), early-onset myopathy, and muscular dystrophy
Items: 1 to 10 of 104
1
2
3
4
5
6
...
10
11
Previous Page
Next Page
Citation Resources
Nature Immunology
Jan, 2025
A critical role of N4-acetylation of cytidine in mRNA by NAT10 in T cell expansion and antiviral immunity
Read More
Nat Cell Biol
Jan, 2013
Characterization of transcriptional networks in blood stem and progenitor cells using high-throughput single-cell gene expression analysis.
Read More
Nature Communications
Jan, 2025
Maternal behavior promotes resilience to adolescent stress in mice through a microglia-neuron axis
Read More
FAQs
Frequently Asked Questions (FAQs)
Are inducible or conditional hACE2 models available for tissue- or time-specific infection studies?
Yes, Cyagen offers inducible and conditional hACE2 mouse models:
K18-hACE2-2A-CreERT2 Mice: Combine hACE2 expression with a tamoxifen-inducible Cre recombinase, allowing temporal control over gene expression. This model is ideal for studying the effects of SARS-CoV-2 infection at specific developmental stages or time points.


ROSA26-LSL-hACE2 Mice: Enable tissue-specific expression of hACE2 when bred with mice expressing Cre recombinase under tissue-specific promoters, facilitating targeted studies of organ-specific infection and pathology.
How precise is the integration of complete human genes? Can specific human isoforms or regulatory elements be accurately mimicked, and what are the limitations in terms of gene size or complexity?
Our proprietary TurboKnockout-Pro™ technology ensures unparalleled precision in complete human gene integration. This advanced approach allows for the seamless insertion of full-length human genes, accurately mimicking endogenous spatial and temporal expression patterns, thereby preserving natural regulation. This capability is critical for faithfully recapitulating human isoforms and their native regulatory elements, even for genes of significant size or complex genomic architecture, providing highly physiologically relevant models for your research.
What are HUGO-GT's capabilities for high-throughput screening and generating custom models quickly?
HUGO-GT™ is designed for accelerated development and high-throughput use. Our ready-to-use models expedite research. For custom projects, our platform ensures rapid generation of new humanized lines, supporting efficient large-scale screening and efficacy studies with exceptional reproducibility.
Given human gene integration, what are the potential immunological responses in the mouse model to the human gene products, and how does HUGO-GT™ account for or mitigate these?
The core principle of HUGO-GT™ is to integrate complete human genes under their native murine promoters, aiming to achieve human gene expression that mimics natural patterns as closely as possible within the mouse. While the study of human gene products in a murine host inherently involves consideration of immunological responses, our meticulous approach to natural regulation and full-length integration is designed to provide a physiologically relevant system. This strategy focuses on studying the human-specific biology and therapeutic interactions, thereby enabling researchers to focus on human-relevant outcomes for their studies.
How do HUGO-GT™ models address potential immunological responses to human gene products in mice?
HUGO-GT™ integrates human genes under native murine promoters for natural expression. While mouse immunological responses to human products are inherent, our approach focuses on providing physiologically relevant systems to study human-specific biology and therapeutic interactions.
What Customers Say About Cyagen
Violet Shimmer
Stanford University
The service provided to us by Cyagen is now in press at Nature as an article.
Scarlett Rouge
Seattle Children’s Hospital
We are very pleased with the state-of-the-art professional transgenic services provided by Cyagen for our study published recently in Nature. We continue to use Cyagen’s transgenic services as it allows us to do better and more efficient research with transgenic mice.
Contact Us
Connect with our experts for your custom animal model needs. Please fill out the form below to start a conversation or request a quote.
Inquiry Details
Main Area of Research
Service(s) of Interest
Gene of Interest
Project Details
Contact Information
Full Name
Email
Phone Number
Organization
Job Role
Country
Cyagen values your privacy. We’d like to keep you informed about our latest offerings and insights. Your preferences:
You may unsubscribe from these communications at any time. See our  Privacy Policy  for details on opting out and data protection.
By clicking the button below, you consent to allow Cyagen to store and process the personal information submitted in this form to provide you the content requested.
Model Library
Model Library
Resources
Resources
Animal Quality
Animal Quality
Get Support
Get Support
Address:
2255 Martin Avenue, Suite E Santa Clara, CA 95050-2709, US
Tel:
800-921-8930 (8-6pm PST)
+1408-963-0306 (lnt’l)
Fax:
408-969-0338
Email:
animal-service@cyagen.com
service@cyagen.us
CRO Services
OncologyOphthalmologyNeuroscienceMetabolic & CardiovascularAutoimmune & InflammatoryGene TherapyAntibody Therapy
About Us
Corporate OverviewOur PartnersCareersContact Us
Social Media
Disclaimer: Pricing and availability of our products and services vary by region. Listed prices are applicable to the specific countries. Please contact us for more information.
Copyright © 2025 Cyagen. All rights reserved.
Privacy Policy
Site Map
Stay Updated with the Latest from Cyagen
Get the latest news on our research models, CRO services, scientific resources, and special offers—tailored to your research needs and delivered straight to your inbox.
Full Name
Email
Organization
Country
Areas of Interest